Compare INMB & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMB | SBI |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 109.7M |
| IPO Year | 2019 | N/A |
| Metric | INMB | SBI |
|---|---|---|
| Price | $1.73 | $7.71 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | ★ 496.6K | 39.5K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | $14,337.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $6.96 |
| 52 Week High | $11.64 | $8.00 |
| Indicator | INMB | SBI |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 36.82 |
| Support Level | $1.75 | $7.74 |
| Resistance Level | $1.90 | $7.87 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.26 | 11.11 |
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.